The prevalence, impact, and multifactorial pathogenesis of diabetic peripheral neuropathy

Advanced Studies in Medicine

Volumn 4, Issue 8 A, 2004, Pages

  Feldman, Eva L ^a   Vincent, Andrea ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; NEUROTROPHIC FACTOR; POLYOL; PROTEIN DERIVATIVE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRANSCRIPTION FACTOR;

BIOACCUMULATION; CELL DAMAGE; CELL DEATH; CORRELATION ANALYSIS; DATA ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCATION; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; MICROANGIOPATHY; MITOCHONDRIAL RESPIRATION; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN PHOSPHORYLATION; REMYELINIZATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TECHNIQUE;

EID: 6344231372     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
2. Hogan P, Dall T, Nickolov P, for the American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabefes Care. 2003;26(3):917-932.
3. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27(6):1458-1486.
4. Boulton AJ, Malik RA. Diabetic neuropathy. Med Clin North Am. 1998;82(4):909-929.
5. Vileikyte L. Diabetic foot ulcers: a quality of life issue. Diabetes Metab Res Rev. 2001;17(4):246-249.
6. Frykberg RG. Epidemiology of the diabetic foot: ulcerations and amputations. Adv Wound Care. 1999;12(3):139-141.
7. Resnick HE, Valsania P, Phillips CL. Diabetes mellitus and nontraumatic lower extremity amputation in black and white Americans: the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, 1971-1992. Arch Intern Med. 1999;159(20):2470-2475.
8. Thomas PK. Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Eur Neurol. 1999;41(suppl I):35-43.
9. Feldman EL, Stevens MJ, Russell JW, Green DA. Diabetic neuropathy. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. Philadelphia, Pa: Lippincott, Williams, & Wilkins; 2001. pp 1391-1399.
10. Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters JR. The prevalence of multiple diabetes-related complications. Diabet Med. 2000;17(2):146-151.
11. Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care. 1997;20(5):836-843.
12. Partanen J, Niskanene L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(2):89-94.
13. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-824. Erratum in: Neurology. 1993;43(11):2345.
14. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinical population. Diabetologia. 1993;36(2):150-154.
15. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetoiogia. 1996;39(11):1377-1384.
16. Molyneaux LM, Constantino MI, McGill M, Zilkens R, Yue DK. Better glycaemic control and risk reduction in type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract. 1998;42(2):77-83.
17. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124(1 pt 2):90-96.
18. Pirart J. Diabetes mellitus and its degenerative complications; a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care. 1978;1:168-188.
19. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-1289.
20. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52(12):2867-2873.
21. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790-1795.
22. Dyck PJ, Lais A, Karnes JL, O'Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol. 1986;19(5):425-439.
23. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol. 1996;55(12):1181-1193.
24. Giannini C, Dyck PJ. Pathologic alterations in human diabetic polyneuropathy. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. 2nd ed. Philadelphia, Pa: W.B. Saunders Company; 1999:279-316.
25. Giannini C, Dyck PJ. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol. 1995;37(4):498-504.
26. Britland ST, Young RJ, Sharma AK, Clark BF. Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes. 1990;39(8):909-913.
27. Timperley WR, Ward JD, Preston EE, Duckworth T, O'Malley BC. A reassessment of vascular factors in relation to intravascular coagulation. Diabetologia. 1976;12(3):237-243.
28. Malik RA, Tesfaye S, Thompson SD, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia. 1993;36(5):454-459.
29. Jaap AJ, Hammersley MS, Shore AC, Tooke JE. Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin dependent) diabetes mellitus. Diabetologia. 1994;37(2):214-216.
30. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48(9):1856-1862.
31. Hogikyan R V, Wald JJ, Feldman EL, Greene DA, Halter JB, Supiano AM. Acute effects of adrenergic-mediated ischemia an nerve conduction in subjects with type 2 diabetes. Metabolism. 1999;48(4):495-500.
32. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44(11):1973-1988.
33. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rates: relation to conduction deficits. Am J Physiol. 1991;261(1 pt 1):E1-E8.
34. Sasaki H, Schmelzer JD, Zollman PJ, Low PA. Neuropathology and blood flow of nerve, spinal roots, and dorsal root ganglia in longstanding diabetic rats. Acta Neuropathol (Berl). 1997;93(2):118-128.
35. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects an nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A. 1991;88(14):6107-6111.
36. Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol. 1989;31:355-438.
37. Theriault M, Dort J, Sutherland G, Zochodne DW. Local human sural nerve blood flow in diabetic and other polyneuropathies. Brain. 1997;120(pt 7):1131-1138.
38. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
39. Vincent AM, Russell JW, Low P, Feldman EL Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev. 2004, In press.
40. Vincent AM, Feldman EL. New insights into the mechanisms of diabetic neuropathy. Rev Endocr Metab Disord. 2004;5(3):227-236.
41. Obrosova IG, Minchenko AG, Vaspuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52(3):864-871.
42. Feldman EL, Sullivan KA, Stevens MJ. Polyolpathway: aldose reductase inhibitors-hope for the future? In: Gries FA, Cameron NE, Low PA, Ziegler D, eds. Textbook of Diabetic Neuropathy. Stuttgart, Germany: Georg Thieme Verlag; 2003. pp 112-115.
43. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-820.
44. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318(20):1315-1321.
45. King RH. The role of glycation in the pathogenesis of diabetic polyneurapathy. Mol Pathol. 2001;54(6):400-408.
46. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129-146. Erratum in: Diabetologia. 2002;45(2):293.
47. Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37-57.
48. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regu ated by oxidant stress. J Biol Chem. 1997;272(28):17810-17814.
49. Xu D, Kyriakis JM. Phosphatidylinositol-3′OH kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products. J Biol Chem. 2003; 278(41):39349-39355.
50. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269(13):9889-9897.
51. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280(5):E685-E694.
52. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of cyclooxygenose-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem. 2003;278(37):34834-34844.
53. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 1997;272(26):16498-16506.
54. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001;50(12):2792-2808.
55. Stevens MJ, Obrosova I, Feldman EL, Greene D. The sorbitol-osmotic and sorbitol-redox hypothesis. In: Diabetes Mellitus: A Fundamental and Clinical Text, Philadelphia, PA: LeRoith D, Taylor SI, Olefsky JM, eds., Lippincott-Raven, 2004. pp 972-982.
56. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes. 1997;46(suppl 2):S31-S37.
57. Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med. 2000; 28(9):1349-1361.
58. Srivastavo AK. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review). Int J Mol Med. 2002;9(1):85-89.
59. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature. 2000;404(6779):787-790.
60. Cameron NE, Cotter MA. Effects of protein kinase C-beta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev. 2002;18(4):315-323.
61. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest. 2003;111(4):431-433.
62. Leinninger G, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2004;9(1):26-53.
63. Kaneto H, Xu G, Song KH, et al. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J Biol Chem. 2001;276(33):31099-31104.
64. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995;18(4):775-794.
65. Wu DC, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A. 2003;100(10):6145-6150.
66. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001;17(3):189-212.
67. Brown GC, Borutaite V. Nitric oxide, cytochrome c and mitochondria. Biochem Soc Symp. 1999;66:17-25.
68. Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res. 2003;37(5):471-480.
69. Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest. 2003;112(7):1049-1057.
70. Russell JW, Golovoy D, Vincent AM, et al. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J. 2002;16(13):1738-1748.
71. Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, Russell JW. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes. 2004;53(3):726-734.
72. Obrosova IG, Stevens MJ, Lang HJ. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology. 2001;62(3):172-180.
73. Pop-Busui R, Sullivan KA, Van Huysen C, et al. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, ond functional deficits. Exp Neurol. 2001;168(2):259-272.
74. Srinivasan S, Stevens MJ, Wiley JW. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes. 2000;49(11):1932-1938.
75. Pop-Busuir, Marinescu V, Van Huysen C, et al. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cycloxygenase inhibition and acetyl-L-carnetine administration. Diabetes. 2002;51(8):2619-2628.
76. Obrasova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and zantioxidative defense. FASEB J. 2002;16(1):123-125.
77. Obrosova IG, Fathallah L, Stevens MJ. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol. 2001;172(1):211-219.
78. Obrosova IG, Minchenko AG, Mariescu V, et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptopotocin-diabetic rats. Diabetologia. 2001;44(9):1102-1110.
79. Stevens MJ. Obrosova I, Gao X, Van Huysen C, Green DA. Effects of DI-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes. 2000;49(6):1006-1015.
80. Vincent AM, Feldman EL. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res. 2002;12(4):193-197.
81. Simmons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol. 2002;15(5):595-603.
82. Delaney CL, Rusell JW, Cheng HL, Feldman EL. Insulin-like growth factor-I and over-expression of BcL-xL prevent glucose-mediated apoptosis in Schwann cells. J Neuropathol Exp Neurol. 2001;60(2):147-160.
83. Apfel SC. Neurotrophic factors and diabetic neuropathy. Eur Neurol. 1999;41(Suppl 1):27-34.
84. Tomilnson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes. 1997;46(Suppl 2):S43-S49.